{
    "eid": "2-s2.0-85037578042",
    "title": "Bringing the mucosa to heal with vedolizumab in patients with inflammatory bowel disease",
    "cover-date": "2017-09-01",
    "subject-areas": [
        {
            "$": "Gastroenterology",
            "@code": "2715"
        }
    ],
    "keywords": [],
    "authors": [
        "Satimai Aniwan"
    ],
    "citedby-count": 0,
    "ref-count": 10,
    "ref-list": [
        "Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease",
        "Vedolizumab as induction and maintenance therapy for ulcerative colitis",
        "Vedolizumab as induction and maintenance therapy for Crohn's disease",
        "Long-term efficacy of vedolizumab for ulcerative colitis",
        "Long-term efficacy of vedolizumab for Crohn's disease",
        "Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists",
        "The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: Results from the US VICTORY consortium",
        "Vedolizumab induces long-term mucosal healing in patients with Crohn's disease and ulcerative colitis",
        "Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed",
        "Vedolizumab as induction and maintenance therapy for Crohn's disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Rochester",
            "affilname": "Mayo Clinic",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Amgen",
        "Eli Lilly and Company",
        "Pfizer",
        "Genentech",
        "Gilead Sciences",
        "Janssen Biotech",
        "AbbVie",
        "Takeda Pharmaceuticals U.S.A.",
        "School of Public Health, University of California Berkeley"
    ]
}